Sam Klempner

Check out our deep dive in MSI-H gastric cancer, now out in @CD_AACR . Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer cancerdiscovery.aacrjournals.org/content/early/…

Delighted to share results of phase 2 ILUSTRO in @NatureMedicine @KlempnerSam @ASCOPost Zolbetuximab+FOLFOX+nivo showed encouraging activity in CLDN18.2+ gastric cancer with mPFS 14.8 months (18months in high CLDN). Supporting the ongoing phase 3 LUCERNA. doi.org/10.1038/s41591…

@amalsargsyan @YJanjigianMD @FilippoPietran4 @MSKCancerCenter @ImmoncInstitute Was great to work with you and the team.

Still surreal - My first paper in Nat Rev Oncol (IF 82) ✨ Our review on metastatic gastric cancer is now live. Grateful to be part of this incredible team led by my mentor Y. @YJanjigianMD with J. Choo, V. Khachatryan, S. Lonardi, F. @FilippoPietran4 R. Sundar & @KlempnerSam

Looking beyond Claudin18.2 in solid tumors. @NatureRevCancer doi.org/10.1038/s41568…

How low can you go? Looking at broader CLDN18.2 cutoffs in GC/GEJ. Nice work from visiting researcher from Korea, courtesy of @JeeyunM @myESMO sciencedirect.com/science/articl…

Congratulations to the Matterhorn study team. FDA approval independent of PD-L1 status. fda.gov/drugs/resource…

With interest in PD-1xVEGF across cancers we add some data from Ram and Pembro. @CIR_AACR @JeeyunM @AnMinae @arnavmehta3 Distinct spatially resolved TME trajectories define benefit from ramucirumab + pembro in refractory PD-L1+ gastric cancer aacrjournals.org/cancerimmunolr…

Now out in @NatureComms. Led by Dr. Liz Carstens in Eric Smith lab @DanaFarber. Modeling on-target/off-tumor tox in CLDN18.2 directed therapy. @KoheiShitara @jonathan_nowak. Supported by @DeGregorioFF. rdcu.be/eN4cg

📢 Ph1/2 FOG-001 — a first-in-class β-catenin/TCF inhibitor — shows early promise in MSS CRC & WPAM+ solid tumors ✅ ORR 43% in non-CRC WPAM+ solid tumors ✅ No grade 4/5 TRAEs ➡️ Combo & monotherapy cohorts underway #Targets25

Nice way to end the week. Pre-print from our team. @arnavmehta3 @JeeyunM @AnMinae, others. Support from @SU2C @AACR. @MGHCancerCenter Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer medrxiv.org/content/10.110…

A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal #cancers and highlight the rapid expansion of claudin18.2-targeting drug development in solid tumors. News & Views from @KlempnerSam and @sundar__raghav @YaleMed @harvardmed #ADCs nature.com/articles/s4159…

Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by @KlempnerSam and myself in @NatureMedicine we discuss two promising Claudin18.2 targeting Antibody-Drug Conjugates. nature.com/articles/s4159…

Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... sciencedirect.com/science/articl… Led by very talented @josephjzhao and Kennedy Ng. @sundar__raghav

Givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in mGEC 🔎Phase I/II 👉ORR 71% 🧐 Interesting activity #ESMOAmbassadors #ESMOGI25 @myESMO

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….

Enjoying interacting with other speakers and discussants during today’s plenary. Exciting new data was presented.

Attending the #AACR25 session on Innovative Paradigms in Immunotherapy Combos in Gastric Cancer? Read speaker @KlempnerSam's recent @CD_AACR paper: Early Immune Remodeling Steers Clinical Response to Frontline Chemoimmunotherapy in Advanced Gastric Cancer doi.org/10.1158/2159-8…

Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial aacrjournals.org/clincancerres/… @JeeyunM @AnMinae @arnavmehta3 @CCR_AACR

Proof of principle in KRAS G12C CRC, analogous to EGFR rechallenge in RAS WT Colon cancer. @MGHCancerCenter @JCOPO_ASCO Anti-KRAS G12C + Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer. ascopubs.org/doi/10.1200/PO…

Cool paper from @ShadiEsfahani and team in @ScienceTM @MGHCancerCenter Development of a fibrin-targeted theranostic for gastric cancer | Science Translational Medicine science.org/doi/10.1126/sc…

SCI members @HowardYChang, @mischellab, and others found that blocking #CHK1 activity leads to death of #ecDNA containing tumor cells and tumor regression in mice with a gastric tumor driven by DNA circles. go.nature.com/3Cy7Blr